STOCK TITAN

Spruce Biosciences (SPRB) Stock Price, News & Analysis

SPRB NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
72 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-26% close of April 21, 2026
1-year change
-64.5% closing prices, November 18, 2025 to November 18, 2026
1-month change
+3% closing prices, October 16, 2026 to November 18, 2026

Company Description

Spruce Biosciences, Inc. (Nasdaq: SPRB) is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. According to company disclosures, Spruce is advancing product candidates that target serious, often fatal conditions where there are currently no U.S. Food and Drug Administration (FDA) approved treatments.

The company’s lead program is tralesinidase alfa enzyme replacement therapy (TA-ERT), which Spruce describes as an investigational therapy for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare, serious, and fatal genetic neurodegenerative disease. Company communications state that there are no FDA-approved therapies for MPS IIIB and that existing management consists of limited palliative care. Spruce has reported integrated long-term clinical data for TA-ERT in patients with MPS IIIB and has received U.S. FDA Breakthrough Therapy Designation for TA-ERT for this indication.

Focus on neurological and rare diseases

Spruce describes itself as a biopharmaceutical company focused on neurological disorders with significant unmet medical need. Its work in MPS IIIB is centered on addressing progressive neurodegeneration associated with deficiency of the enzyme N-acetyl-alpha-glycosaminidase (NAGLU). Company materials explain that accumulation of toxic levels of cerebral spinal fluid heparan sulfate in the brain underlies the pathophysiology of MPS IIIB and leads to brain atrophy, cognitive and developmental impairment, behavioral issues, motor deficits, and ultimately severe dementia and early death.

In addition to TA-ERT, Spruce has discussed development activities related to tildacerfont, an oral small-molecule antagonist of the CRF1 receptor, being studied in major depressive disorder (MDD) under a license, development, and option agreement with HMNC Holding GmbH. Under that agreement, HMNC is funding and conducting a Phase 2 proof-of-concept study (the TAMARIND trial) in MDD patients screened with HMNC’s Cortibon companion diagnostic. Company updates also reference development activities related to SPR202, described as an anti-corticotrophin releasing hormone monoclonal antibody for the treatment of congenital adrenal hyperplasia.

TA-ERT mechanism and clinical data

Spruce describes TA-ERT as a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU), intended as an enzyme replacement therapy for patients with MPS IIIB who lack rhNAGLU enzyme activity. According to the company, TA-ERT is expected to restore NAGLU enzyme activity in the central nervous system following intracerebroventricular injection. Because rhNAGLU typically lacks mannose-6-phosphate residues needed for efficient cellular uptake, TA-ERT is fused to an insulin-like growth factor 2 peptide designed to bind to cation-independent mannose-6-phosphate receptors on cell surfaces and enable internalization and lysosomal delivery.

Company-reported integrated group-level clinical data from studies 201, 202, and 401 in patients with MPS IIIB indicate that TA-ERT therapy:

  • Profoundly and durably reduced cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE) to normal or near-normal levels over a multi-year period.
  • Was associated with stabilization of cognitive function, as measured by the Bayley-III Cognitive Raw Score, relative to declines observed in untreated natural history cohorts.
  • Was associated with stabilization of cortical grey matter volume (CGMV) after an initial period thought to reflect intracellular clearance of stored substrate.

Spruce reports that TA-ERT exposure for up to several years has demonstrated what it characterizes as an adequate safety profile in this serious and fatal disease, with no deaths reported in the referenced interventional and extension studies. The company notes that adverse events related to the intracerebroventricular device were consistent with other therapies administered by this route.

Regulatory interactions and development pathway

Spruce has disclosed multiple regulatory interactions regarding TA-ERT. The company reports that the FDA has:

  • Granted Breakthrough Therapy Designation for TA-ERT for the treatment of MPS IIIB.
  • Confirmed that CSF HS-NRE is a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval.

Spruce has publicly discussed its intention to pursue a biologics license application (BLA) submission for TA-ERT for MPS IIIB under the accelerated approval pathway. Company updates reference planning for pre-launch commercial activities and a potential transition to a commercial-stage organization if TA-ERT is approved.

Financing and capital structure activities

Spruce’s disclosures describe several financing and capital markets events that support its development plans. These include:

  • A private placement financing pursuant to a Securities Purchase Agreement with institutional investors, involving the sale of common stock and pre-funded warrants, with gross proceeds described as approximately $50.0 million. The company states that this financing is intended to advance TA-ERT for MPS IIIB through BLA submission and potential U.S. commercial launch.
  • A loan and security agreement with Avenue Venture Opportunities Fund II, L.P., providing access to term loans in an aggregate principal amount of up to $50.0 million, structured in multiple tranches tied to specified regulatory and commercial milestones related to TA-ERT for MPS IIIB. The loans are secured by liens on the company’s assets, including intellectual property, subject to agreed exceptions.
  • The planned issuance of a warrant to the lender to purchase shares of common stock, with terms linked to future equity financing pricing and subject to beneficial ownership limitations.
  • A reverse stock split of the company’s common stock at a ratio of 1-for-75, which the company states was intended to help regain compliance with Nasdaq’s minimum bid price requirement.

Spruce has also described its efforts to resume and maintain listing on the Nasdaq Capital Market. Company announcements detail conditional Nasdaq approval to resume trading, implementation of the reverse stock split, and subsequent resumption of trading under the ticker symbol SPRB on the Nasdaq Capital Market.

Corporate governance and equity incentives

The company’s SEC filings and press releases provide insight into its governance and compensation practices. For example, Spruce has reported:

  • The appointment of Keli Walbert to its board of directors as a Class I director and member of the compensation committee, along with a stock option grant and cash retainers in accordance with its non-employee director compensation policy.
  • Resignations of certain directors, with the company stating in each case that the resignations were not the result of any disagreement with the company on matters relating to operations, policies, or practices.
  • An option repricing for certain outstanding stock options held by employees and directors, reducing exercise prices to a level based on a trailing volume-weighted average price, subject to a defined retention period and other conditions. The company explains this repricing as a measure to retain and motivate option holders without incurring additional dilution from new equity grants or significant additional cash compensation.

Business model and sector context

Based on its own descriptions, Spruce operates as a late-stage biopharmaceutical developer in the area of neurological and rare diseases. Its activities include discovery, acquisition, and clinical development of product candidates such as TA-ERT, tildacerfont, and SPR202, as well as regulatory engagement and preparation for potential commercialization. The company’s financing strategy, as described in its public disclosures, combines equity offerings, venture debt, and capital markets transactions to fund research, development, and potential launch activities.

Spruce’s work in MPS IIIB positions it within the rare disease and enzyme replacement therapy segment of the pharmaceutical preparation manufacturing industry. Its collaboration with HMNC Holding GmbH on tildacerfont and Cortibon reflects an interest in precision approaches in psychiatry, targeting biologically defined subtypes of major depressive disorder linked to hypothalamic-pituitary-adrenal axis dysregulation.

Stock information

Spruce Biosciences’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the Nasdaq Capital Market under the symbol SPRB, as indicated in the company’s SEC filings. The company has discussed periods of trading suspension, trading on the OTCQB, and subsequent relisting on Nasdaq following compliance efforts related to minimum bid price requirements.

Key risks and considerations

Spruce’s public statements emphasize that many of its disclosures are forward-looking and subject to risks and uncertainties. The company notes that actual results may differ materially from expectations regarding regulatory timelines, potential approvals, clinical outcomes, financing, and its ability to fund operating plans. Investors reviewing Spruce Biosciences typically consult its SEC filings, including Forms 10-K, 10-Q, and 8-K, for detailed risk factors and financial information.

Stock Performance

$40.84
+0.86%
+0.35
Last updated: at
-64.5%
Performance 1 year
$117.4M

Spruce Biosciences (SPRB) closed at $40.84 on November 18, 2026. Over the past 12 months, the price has lost 64.5%.

See what a $1,000 investment in SPRB would be worth today

Average down calculator for SPRB

SPRB Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Spruce Biosciences has 10 recent news articles, with the latest published on . Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings. View all SPRB news →

Financial Highlights

Spruce Biosciences reported operating income of -$36.5M in FY2025, and net income was -$39.0M. Diluted earnings per share stood at -$50.83. The company generated -$33.3M in operating cash flow. The current ratio was 5.17, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$39.0M
Net Income (FY2025)
-$33.3M
Operating Cash Flow

Upcoming Events

DEC
2026
December 2026 Regulatory

TA-ERT accelerated approval

Spruce to seek accelerated FDA approval for TA-ERT in MPS IIIB, targeted for December 2026; material regulatory milestone.
DEC
2026
December 2026 Clinical

Confirmatory study start

Spruce targets initiation of TA-ERT confirmatory study in December 2026 to support an accelerated approval pathway.
DEC
2026
December 2026 Operations

Manufacturing qualification batch

Second manufacturing qualification batch for TA-ERT is targeted for December 2026 to support commercial readiness.
DEC
2026
December 2026 Regulatory

TA-ERT marketing application

Spruce plans to submit a TA-ERT marketing application in December 2026 to the FDA; possible U.S. launch in 2027 if approved.
YEAR
2027
2027 Product

Commercial launch targeted

Planned commercial launch of tralesinidase alfa (TA-ERT) for MPS IIIB targeted in 2027; timing pending regulatory approval.
H1
2027
H1 2027 Corporate

Adrenyx share distribution

Pro rata distribution of Adrenyx shares to Spruce shareholders in H1 2027, subject to board approval, SEC registration and Nasdaq approval.
JUN
15
June 15, 2027 Corporate

First RSU vesting

First annual vesting of ~875 RSUs to each VP on 2027-06-15 under the 2026 Inducement Plan; may lead to share issuance/dilution.
JUN
15
June 15, 2028 Corporate

Second RSU vesting

Second annual vesting of ~875 RSUs to each VP on 2028-06-15 under the 2026 Inducement Plan; monitor potential dilution impact.
JUN
15
June 15, 2029 Corporate

Third RSU vesting

Third annual vesting of ~875 RSUs to each VP on 2029-06-15 under the 2026 Inducement Plan; may result in incremental share issuance.
JUN
15
June 15, 2030 Corporate

Fourth RSU vesting

Final annual vesting of ~875 RSUs to each VP on 2030-06-15 under the 2026 Inducement Plan; completes four-year inducement schedule.

Spruce Biosciences has 10 upcoming scheduled events. The next event, "TA-ERT accelerated approval", is expected in December 2026. Investors can track these dates to stay informed about potential catalysts that may affect the SPRB stock price.

Short Interest History

Last 12 Months

Short interest in Spruce Biosciences (SPRB) currently stands at 531.4 thousand shares, up 1.8% from the previous reporting period, representing 22.7% of the float. Since November 2025, short interest has increased by 420.9%.

Days to Cover History

Last 12 Months

Days to cover for Spruce Biosciences (SPRB) currently stands at 7.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 595%. Across the settlements charted above, it has ranged from 1.0 to 10.4 days.

SPRB Company Profile & Sector Positioning

Spruce Biosciences (SPRB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SPRB often look at related companies in the same sector, including Minerva Neurosciences, Inc (NERV), Equillium, Inc. (EQ), Jyong Biotech Ltd. (MENS), Foghorn Therapeutics Inc. (FHTX), and Zura Bio Limited (ZURA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SPRB's relative position within its industry.

Frequently Asked Questions

The current stock price of Spruce Biosciences (SPRB) is $40.84 as of November 18, 2026.

The market cap of Spruce Biosciences (SPRB) is approximately $117.4M. Learn more about what market capitalization means .

The FY2025 revenue of Spruce Biosciences (SPRB) is $0, from its most recent completed fiscal year.

The FY2025 net income of Spruce Biosciences (SPRB) is -$39.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Spruce Biosciences (SPRB) is -$50.83 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Spruce Biosciences (SPRB) is -$33.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Spruce Biosciences (SPRB), current assets divided by current liabilities, was 5.17 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Spruce Biosciences (SPRB) is -$36.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Its lead program, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare, serious, and fatal genetic disease for which there are currently no FDA-approved therapies, according to the company.

Tralesinidase alfa enzyme replacement therapy (TA-ERT) is described by Spruce as a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). It is intended as an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B (MPS IIIB) who lack rhNAGLU enzyme activity. The therapy is expected to restore NAGLU activity in the central nervous system following intracerebroventricular injection.

Spruce Biosciences reports that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The company also states that the FDA has confirmed cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE) as a surrogate biomarker reasonably likely to predict clinical benefit, which could serve as a basis for accelerated approval.

According to company announcements, integrated long-term data from clinical studies 201, 202, and 401 show that TA-ERT therapy led to a rapid, profound, and durable reduction of CSF HS-NRE to normal or near-normal levels, stabilization of cortical grey matter volume, and stabilization of cognitive function in treated children relative to declines observed in untreated natural history cohorts. Spruce also reports that TA-ERT has demonstrated an adequate safety profile over several years of exposure in the studied population.

In addition to TA-ERT, Spruce has discussed tildacerfont, a potent and highly selective oral small-molecule antagonist of the CRF1 receptor, being studied in major depressive disorder (MDD) under a license, development, and option agreement with HMNC Holding GmbH. The company has also referenced SPR202, described as an anti-corticotrophin releasing hormone monoclonal antibody for the treatment of congenital adrenal hyperplasia.

Spruce has described multiple financing activities, including a private placement with institutional investors involving common stock and pre-funded warrants, which the company states is expected to provide approximately $50.0 million in gross proceeds to advance TA-ERT for MPS IIIB. The company has also entered into a loan and security agreement with Avenue Venture Opportunities Fund II, L.P., providing access to up to $50.0 million in term loans in tranches tied to regulatory and commercial milestones related to TA-ERT.

According to its SEC filings, Spruce Biosciences’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the Nasdaq Capital Market under the ticker symbol SPRB. The company has reported periods of trading on the OTCQB and subsequent resumption of trading on Nasdaq following efforts to comply with minimum bid price requirements.

Spruce describes MPS IIIB as an ultra-rare, serious, and fatal genetic disease caused by deficiency in N-acetyl-alpha-glycosaminidase (NAGLU), an enzyme required for the catabolism of heparan sulfate in lysosomes. The company notes that toxic accumulation of cerebral spinal fluid heparan sulfate in the brain leads to progressive neurodegeneration, brain atrophy, cognitive and developmental impairment, behavioral problems, motor deficits, and ultimately severe dementia, loss of motor function, seizures, and early death. It states that there are currently no FDA-approved therapies for MPS IIIB.

Spruce has announced a 1-for-75 reverse stock split of its issued and outstanding common stock, which it states was intended to help regain compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has also reported conditional Nasdaq approval to resume trading, trading on a split-adjusted basis, and subsequent resumption of trading under the SPRB symbol on the Nasdaq Capital Market.

Company filings describe a non-employee director compensation policy that provides for stock option grants and cash retainers for directors. Spruce has also reported an option repricing for certain outstanding stock options held by employees and directors, reducing exercise prices to a level based on a thirty-day trailing volume-weighted average price. The company explains that this repricing, which includes a defined retention period, was designed to retain and motivate option holders without incurring additional dilution from significant new equity grants or substantial additional cash compensation.